About the Study
Migraines are a common and debilitating neurological disorder that affects approximately 15% of the adult population. Migraines can last from 4 – 72 hours if left untreated. Migraine sufferers experience moderate to severe pain that can be throbbing or pulsing or accompanied by nausea or sensitivity to light or sound.
Many of the treatments on the market for migraines are triptans (I.E. Imitrex). Triptans are not advised for those who have any cardiovascular events since they have properties that can constrict your blood vessels. Recent estimates indicate that there are 2.6 million Americans with migraines who have a cardiovascular event, condition, or procedure, demonstrating the need for a non-triptan migraine treatment.
The purpose of this research study is to examine an investigational nasal spray for the treatment of an acute migraine headache. Rochester Clinical Research is currently enrolling individuals over the age of 18 years old who experience 2-8 migraines per month. The study drug is a CGRP receptor blocker administered through a nasal spray. The study will last approximately one year long with 17 visits to our office.
Study related care is provided to participants at no cost. Compensation for time and travel may be available for those who qualify.
- Over the age of 18 years old
- History of migraines (with or without aura) for more than one year with age of onset under 50.
- 2-8 moderate to severe migraine attacks per month in each of the last 3 months
- Please note, other conditions may apply.